{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-019112","form_type":"8-K","ticker":"AKTX","cik":"0001541157","company_name":"Akari Therapeutics Plc","filed_at":"2025-10-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.692148+00:00","generated_at":"2026-05-17T02:29:54.231011+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Akari Therapeutics appoints Kameel Farag as interim CFO","bullets":["Kameel Farag appointed interim CFO effective October 22, 2025; succeeds Torsten Hombeck.","Compensation: $18,000/month cash + $12,000 in RSUs for Oct-Dec 2025; increases in Jan-Feb 2026.","Consultant also entitled to 1.0% of capital raise proceeds up to $200,000 cap (0.5% after term).","Consulting agreement runs through February 16, 2026, with possible month-to-month extensions."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-019112","json":"https://secwatch.observer/filing/0001493152-25-019112.json","markdown":"https://secwatch.observer/filing/0001493152-25-019112.md","text":"https://secwatch.observer/filing/0001493152-25-019112.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1541157/000149315225019112/0001493152-25-019112-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1541157/000149315225019112/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:29:54.231011+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}